+409.1%
HUT vs GSK
+65.2%
+343.9%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.3% | +2.4% | +5.9% | +9.3% |
| 7D | +3.7% | +4.9% | -1.2% | +6.5% |
| 30D | -32.3% | +10.8% | -43.2% | -28.8% |
| 3M | -35.6% | -1.8% | -33.8% | -34.8% |
| 6M | -42.1% | +4.1% | -46.2% | -40.0% |
| YTD | +24.1% | +7.9% | +16.2% | +32.3% |
| 1Y | +27.9% | +14.4% | +13.4% | +39.4% |
| 3Y | +409.1% | +68.1% | +341.0% | +399.1% |
| All | +409.1% | +65.2% | +343.9% | +399.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling